The Year 2019 in Japanese Health Technology Assessment
With one of the highest life expectancies among countries and an increasingly aging population, Japan is at a juncture where there are more... In DRG Blog/ March, 2020 Early Access Pathways: SMC Interim Decisions
Health Technology Assessment (HTA) agencies across the globe are witnessing a paradigm shift in their drug assessment processes. From formulating... In DRG Blog/ November, 2019 Evolution of Health Technology Assessment (HTA) in China
Asian pharma markets have been in the limelight for some time now for increasingly dynamic drug policies, expanding coverage, increasing... In DRG Blog/ July, 2019 Growing Patient Involvement in Health Technology Assessment (HTA)
Health technology assessment (HTA) agencies such as National Institute for Health and Care Excellence (NICE - UK), Scottish Medicines Consortium (... In DRG Blog, Market Access/ May, 2019 Taiwan and Innovative Contracting – A Look at What's Ahead
Global healthcare systems are noticing a shift towards value-based healthcare with an increased focus on managing rising expenses. Innovative... In DRG Blog, Market Access/ October, 2018 Universal Health Insurance in Indonesia
Is the 2019 Target Still in Sight? In 2014, the Indonesian government set out on a journey towards an ambitious destination: mandatory universal... In DRG Blog, Market Access/ October, 2017 Market Access Challenges in 2017: Drug Expenditure Targets in Taiwan Will Continue to Complicate Market Access Landscape
Starting in 2006, the National Health Insurance program in Taiwan faced the ordeal of recurrent budgetary deficits. An ageing population was and... In DRG Blog, Market Access/ March, 2017 FDA up for Regulatory Reforms: 21st Century Cures Act
Earlier this year, I talked about the challenges 21st Century Cures Act was facing in Congress. Since then, the Health, Education, Labor and... In DRG Blog, Market Access/ December, 2016 Is Depakine the new Mediator?
Seven years ago, the former French drug regulatory agency AFSSAPS (Agence française de sécurité sanitaire des produits de santé) was in deep... In DRG Blog, Market Access/ September, 2016 Affordable HCV Treatment in Developing and Middle-Income Markets – a Dream or Reality?
The launch of new and incredibly effective hepatitis C treatments has provided a breakthrough in recent years. Patients who had failed on previous... In DRG Blog, Market Access/ May, 2016 Karnataka Seeks to Establish Rare Diseases and Orphan Drug Policy
With just 4.2% of its GDP being spent on healthcare in 2015-2016 – and a paltry 1.2% of GDP being public health spending – optimal healthcare... In DRG Blog, Market Access/ April, 2016 As Rare Disease Day Approaches, Key Legislation Faces Challenges in Congress
With Rare Disease Day approaching Feb. 29, it’s a good time to take stock on how far treatment of these indications has come and what the future... In DRG Blog, Market Access/ February, 2016